Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 122

1.

Intellectual performance of kidney transplant recipients' offspring: a cross-sectional, multicenter study.

Morales-Buenrostro LE, Alberu J, Mancilla-Urrea E, Vélez-García A, Espinoza-Pérez R, Cruz-Santiago J, Parra-Michel R, Parra-Avila I, Flores-Nava G, Caballero-Andrade G, Niebla-Cardenas A, Pérez-Avendaño R, Angulo-Dominguez A, Lascarez S, Sánchez-Román S.

J Matern Fetal Neonatal Med. 2017 Oct 8:1-8. doi: 10.1080/14767058.2017.1384805. [Epub ahead of print]

PMID:
28988522
2.

Graft immunologic events in deceased donor kidney transplant recipients with preformed HLA-donor specific antibodies.

Ixtlapale-Carmona X, Arvizu A, De-Santiago A, González-Tableros N, López M, Castelán N, Marino LA, Uribe-Uribe NO, Contreras AG, Vilatobá M, Morales-Buenrostro LE, Alberú J.

Transpl Immunol. 2017 Sep 30. pii: S0966-3274(17)30096-5. doi: 10.1016/j.trim.2017.09.006. [Epub ahead of print]

PMID:
28974434
3.

KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors.

Lentine KL, Kasiske BL, Levey AS, Adams PL, Alberú J, Bakr MA, Gallon L, Garvey CA, Guleria S, Li PK, Segev DL, Taler SJ, Tanabe K, Wright L, Zeier MG, Cheung M, Garg AX.

Transplantation. 2017 Aug;101(8S Suppl 1):S1-S109. doi: 10.1097/TP.0000000000001769.

4.

Summary of Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors.

Lentine KL, Kasiske BL, Levey AS, Adams PL, Alberú J, Bakr MA, Gallon L, Garvey CA, Guleria S, Li PK, Segev DL, Taler SJ, Tanabe K, Wright L, Zeier MG, Cheung M, Garg AX.

Transplantation. 2017 Aug;101(8):1783-1792. doi: 10.1097/TP.0000000000001770. Review.

5.

Methylation of FOXP3 TSDR Underlies the Impaired Suppressive Function of Tregs from Long-term Belatacept-Treated Kidney Transplant Patients.

Alvarez Salazar EK, Cortés-Hernández A, Alemán-Muench GR, Alberú J, Rodríguez-Aguilera JR, Recillas-Targa F, Chagoya de Sánchez V, Cuevas E, Mancilla-Urrea E, Pérez García M, Mondragón-Ramírez G, Vilatobá M, Bostock I, Hernández-Méndez E, De Rungs D, García-Zepeda EA, Soldevila G.

Front Immunol. 2017 Mar 3;8:219. doi: 10.3389/fimmu.2017.00219. eCollection 2017.

6.

Anti-HLA-DQ antibodies are highly and independently related to the C1q-binding capacity of HLA antibodies.

Arreola-Guerra JM, Morales-Buenrostro LE, Granados J, Castelán N, de Santiago A, Arvizu A, Gonzalez-Tableros N, López M, Vilatobá M, Alberú J.

Transpl Immunol. 2017 Mar;41:10-16. doi: 10.1016/j.trim.2017.02.003. Epub 2017 Mar 8.

PMID:
28284929
7.

Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.

Grinyó JM, Del Carmen Rial M, Alberu J, Steinberg SM, Manfro RC, Nainan G, Vincenti F, Jones-Burton C, Kamar N.

Am J Kidney Dis. 2017 May;69(5):587-594. doi: 10.1053/j.ajkd.2016.09.021. Epub 2016 Nov 23.

8.

C1Q Assay Results in Complement-Dependent Cytotoxicity Crossmatch Negative Renal Transplant Candidates with Donor-Specific Antibodies: High Specificity but Low Sensitivity When Predicting Flow Crossmatch.

Arreola-Guerra JM, Castelán N, de Santiago A, Arvizu A, Gonzalez-Tableros N, López M, Salcedo I, Vilatobá M, Granados J, Morales-Buenrostro LE, Alberú J.

J Transplant. 2016;2016:2106028. doi: 10.1155/2016/2106028. Epub 2016 Sep 4.

9.

Impact of pretransplant exposure to allosensitization factors generating HLA antibodies in the Luminex era.

Guichard-Romero A, Marino-Vazquez LA, Castelán N, López M, González-Tableros N, Arvizu A, De Santiago A, Alberú J, Morales-Buenrostro LE.

Transpl Immunol. 2016 Sep;38:33-9. doi: 10.1016/j.trim.2016.08.003. Epub 2016 Aug 20.

PMID:
27553730
10.

Facing the Metabolic Syndrome Epidemic in Living Kidney Donor Programs.

Mejía-Vilet JM, Córdova-Sánchez BM, Arreola-Guerra JM, Alberú J, Morales-Buenrostro LE.

Ann Transplant. 2016 Jul 22;21:456-62.

11.

Pretransplant angiotensin II type 1-receptor antibodies are a risk factor for earlier detection of de novo HLA donor-specific antibodies.

Cuevas E, Arreola-Guerra JM, Hernández-Méndez EA, Salcedo I, Castelán N, Uribe-Uribe NO, Vilatobá M, Contreras-Saldívar AG, Sánchez-Cedillo AI, Ramírez JB, de Rungs D, Granados J, Morales-Buenrostro LE, Alberú J.

Nephrol Dial Transplant. 2016 Oct;31(10):1738-45. doi: 10.1093/ndt/gfw204. Epub 2016 May 24.

PMID:
27220757
12.

Tacrolimus Trough Levels as a Risk Factor for Acute Rejection in Renal Transplant Patients.

Arreola-Guerra JM, Serrano M, Morales-Buenrostro LE, Vilatobá M, Alberú J.

Ann Transplant. 2016 Feb 16;21:105-14.

13.
14.

Increased phosphorylation of the renal Na+-Cl- cotransporter in male kidney transplant recipient patients with hypertension: a prospective cohort.

Rojas-Vega L, Jiménez-Vega AR, Bazúa-Valenti S, Arroyo-Garza I, Jiménez JV, Gómez-Ocádiz R, Carrillo-Pérez DL, Moreno E, Morales-Buenrostro LE, Alberú J, Gamba G.

Am J Physiol Renal Physiol. 2015 Nov 15;309(10):F836-42. doi: 10.1152/ajprenal.00326.2015. Epub 2015 Sep 2.

PMID:
26336164
15.

Is Mexico Ready for Face Transplantation?

Iglesias M, Butrón P, Osuna-Leal AI, Abarca-Perez L, Sosa-Ascencio MJ, Moran-Romero MA, Cruz-Reyes AU, Pineda-Gutierrez FJ, Leon-Lopez DA, García-Alvarez MN, Alberu J, Vilatoba M, Leal-Villalpando RP, Zamudio-Bautista J, Acosta-Nava VM, Gonzalez J.

Transplant Proc. 2015 Jul-Aug;47(6):1998-2002. doi: 10.1016/j.transproceed.2015.05.020. Review.

PMID:
26293088
16.

Effect of Ramipril on Urinary Protein Excretion in Maintenance Renal Transplant Patients Converted to Sirolimus.

Mandelbrot DA, Alberú J, Barama A, Marder BA, Silva HT Jr, Flechner SM, Flynn A, Healy C, Li H, Tortorici MA, Schulman SL.

Am J Transplant. 2015 Dec;15(12):3174-84. doi: 10.1111/ajt.13384. Epub 2015 Jul 14.

17.

Changes in frequency of delayed graft function in deceased donor renal transplant recipient in a tertiary care center in Mexico.

Noriega-Salas AL, Alberú J, Sánchez-Cedillo AI, Navarro-Vargas L, Visag V, Vintimilla-Moscoso A, López-Jiménez JL, Madrigal-Bustamante J, Contreras AG, Vilatobá-Chapa M.

Rev Invest Clin. 2015 Mar-Apr;67(2):89-97.

18.

Pre-transplant angiotensin II type 1receptor antibodies: a risk factor for decreased kidney graft function in the early post-transplant period?

Hernández-Méndez EA, Arreola-Guerra JM, Morales-Buenrostro LE, Ramírez JB, Calleja S, Castelán N, Salcedo I, Vilatobá M, Contreras AG, Gabilondo B, Granados J, Alberú J.

Rev Invest Clin. 2014 May-Jun;66(3):218-24.

PMID:
25695237
19.

C1q Assay Results in Complement-Dependent Cytotoxicity Crossmatch Negative Renal Transplant Candidates with Donor-Specific Antibodies: High Specificity But Low Sensitivity When Predicting Flow Crossmatch.

Arreola-Guerra JM, Morales-Buenrostro LE, Castelán N, de Santiago A, Arvizu A, Gonzalez-Tableros N, López M, Vilatobá M, Granados J, Alberú J.

Clin Transpl. 2015;31:285-292.

PMID:
28514590
20.

A Three-Gene Assay for Monitoring Immune Quiescence in Kidney Transplantation.

Roedder S, Li L, Alonso MN, Hsieh SC, Vu MT, Dai H, Sigdel TK, Bostock I, Macedo C, Metes D, Zeevi A, Shapiro R, Salvatierra O, Scandling J, Alberu J, Engleman E, Sarwal MM.

J Am Soc Nephrol. 2015 Aug;26(8):2042-53. doi: 10.1681/ASN.2013111239. Epub 2014 Nov 26.

Supplemental Content

Loading ...
Support Center